We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sigbjørn Berentsen

Sigbjørn Berentsen MD, PhD

Consultant Hematologist and Senior Researcher, Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway

Dr. Berentsen graduated in 1973 from the University of Bergen, Norway, and received his PhD degree in 2004; title of the thesis: “Primary chronic cold agglutinin disease.” He had his clinical training in internal medicine at Haugesund Hospital and Stavanger University Hospital, and his hematology training at St. Olav University Hospital (Trondheim) and Haukeland University Hospital (Bergen). Dr. Berentsen has held positions as a consultant hematologist at Haugesund Hospital, Haukeland University Hospital and Oslo University Hospital, and he was an associate professor at the University of Bergen 2004-2016. Currently, he is a consultant hematologist and senior researcher at the Department of Research and Innovation, Haugesund Hospital.

Dr. Berentsen has authored numerous PubMed referenced, original and review articles and a couple of major textbook chapters. He has been interested in autoimmune hemolytic anemia, lymphoproliferative disorders, and complement-mediated diseases. His current main field of research is cold agglutinin disease (CAD), for which he has authored most of the published studies of B-cell directed therapies. He is a coauthor of the CAD section in UpToDate, and he has given invited lectures at several international meetings and conferences, including ASH.

Disclosures

Dr. Berentsen has received lecture honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), and Janssen-Cilag, and consultancy and advisory board honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Momenta Pharmaceuticals, and Sobi.